PMID- 36438821 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221129 IS - 1663-9812 (Print) IS - 1663-9812 (Electronic) IS - 1663-9812 (Linking) VI - 13 DP - 2022 TI - A comprehensive comparison of medication strategies for platinum-sensitive recurrent ovarian cancer: A Bayesian network meta-analysis. PG - 1010626 LID - 10.3389/fphar.2022.1010626 [doi] LID - 1010626 AB - Background: The Platinum-based combination has been proven to have an outstanding effect on patients with platinum-sensitive recurrent ovarian cancer (PSROC), but the best scientific combination has not been established yet. The present study is aimed to seek the best treatment plan for PSROC. Methods: We did a systematic review and Bayesian network meta-analysis, during which lite before March 2022 were retrieved on PubMed, Embase, Web of Science, and Cochrane Central Registry of Controlled databases. We included randomized controlled clinical trials comparing chemotherapy combinations with other treatments for patients with PSROC. The important outcomes concerned were progression-free survival (PFS) (the primary outcome), overall survival (OS), objective response rate (ORR), adverse events (AEs), and AEs-related discontinuation. All outcomes were ranked according to the surface under the cumulative ranking curve. Results: 26 trials involving 10441 patients were retrieved in this study. For the initial treatment of PSROC, carboplatin plus pegylated liposomal doxorubicin (PLD) plus bevacizumab had the best PFS [hazard ratio (HR) 0.59, 95% credible interval (CI) 0.51-0.68]; Carboplatin plus paclitaxel plus bevacizumab resulted in the best OS (HR 1.22, 95% CI 1.09-1.35) and ORR [odds ratio (OR) 1.22, 95% CI 1.09-1.35]. For the maintenance therapy in PSROC, poly (ADP-ribose) polymerase inhibitors (PARPi) following platinum-based chemotherapy provided the best PFS (HR 0.64, 95% CI 0.61-0.68), the highest frequency of adverse events of grade three or higher (OR 0.18, 95% CI 0.07-0.44) but the treatment discontinuation was generally low. Subgroup analysis suggested that trabectedin plus PLD was comparable to single platinum in prolonging PFS in the platinum-free interval (6-12 months). Conclusion: Both platinum-based chemotherapy plus PARPi and platinum-based chemotherapy plus bevacizumab had higher survival benefits than other treatments in PSROC. Trabectedin plus PLD might be a potential alternative treatment strategy for the partially platinum-sensitive subpopulation with intolerance to platinum. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/display_record.php?], identifier [CRD42022326573]. CI - Copyright (c) 2022 Liu, Huang, Li, Wan, Jiang, Yang, Chiampanichayakul, Tima, Anuchapreeda and Wu. FAU - Liu, Yuanzhi AU - Liu Y AD - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. FAU - Huang, Yilan AU - Huang Y AD - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. AD - School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. FAU - Li, Jingyan AU - Li J AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. AD - Department of Cardiovascular Surgery, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. FAU - Wan, Shengli AU - Wan S AD - Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China. AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. FAU - Jiang, Nan AU - Jiang N AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. AD - School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. FAU - Yang, Jie AU - Yang J AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. AD - School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. FAU - Chiampanichayakul, Sawitree AU - Chiampanichayakul S AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. FAU - Tima, Singkome AU - Tima S AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. AD - Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai, Thailand. FAU - Anuchapreeda, Songyot AU - Anuchapreeda S AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. AD - Center for Research and Development of Natural Products for Health, Chiang Mai University, Chiang Mai, Thailand. FAU - Wu, Jianming AU - Wu J AD - Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand. AD - School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, China. AD - Key Laboratory of Medical Electrophysiology of Ministry of Education of China, Medical Key Laboratory for Drug Discovery and Druggability Evaluation of Sichuan Province, Luzhou Key Laboratory of Activity Screening and Druggability Evaluation for Chinese Materia Medica, Southwest Medical University, Luzhou, Sichuan, China. LA - eng PT - Systematic Review DEP - 20221110 PL - Switzerland TA - Front Pharmacol JT - Frontiers in pharmacology JID - 101548923 PMC - PMC9691266 OTO - NOTNLM OT - chemotherapy OT - initial therapy OT - maintenance therapy OT - medication strategies for platinum-sensitive recurrent ovarian cancer recurrent ovarian OT - network meta-analysis OT - platinum-sensitive COIS- The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/11/29 06:00 MHDA- 2022/11/29 06:01 PMCR- 2022/11/10 CRDT- 2022/11/28 04:24 PHST- 2022/08/03 00:00 [received] PHST- 2022/10/26 00:00 [accepted] PHST- 2022/11/28 04:24 [entrez] PHST- 2022/11/29 06:00 [pubmed] PHST- 2022/11/29 06:01 [medline] PHST- 2022/11/10 00:00 [pmc-release] AID - 1010626 [pii] AID - 10.3389/fphar.2022.1010626 [doi] PST - epublish SO - Front Pharmacol. 2022 Nov 10;13:1010626. doi: 10.3389/fphar.2022.1010626. eCollection 2022.